Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
11/2003
11/06/2003WO2003091274A2 Use of alpha-s2 casein precursor-derived peptided
11/06/2003WO2003091259A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003WO2003091258A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003091257A1 [1,4]DIAZOCINO [7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS
11/06/2003WO2003091253A1 Nitrosated imidazopyridines
11/06/2003WO2003091251A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-1j]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003WO2003091250A1 [1,4]diazepino[6,7,1-ij]quinoline derivatives as anti psychotic and antiobesity agents
11/06/2003WO2003091247A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003WO2003091245A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism
11/06/2003WO2003091242A1 Novel thiol derivative, process for producing the same and use thereof
11/06/2003WO2003091239A1 Estrogen receptor modulators
11/06/2003WO2003091236A1 Imidazolinylmethyl aralkylsulfonamides
11/06/2003WO2003091232A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
11/06/2003WO2003091229A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
11/06/2003WO2003091227A1 Tachykinin receptor antagonists
11/06/2003WO2003091226A1 Triazole derivatives as tachykinin receptor antagonists
11/06/2003WO2003091225A1 Substituted pyrazine derivatives
11/06/2003WO2003091223A1 Pyrimidine derivative
11/06/2003WO2003091204A1 Phenethanolamine derivatives
11/06/2003WO2003090912A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
11/06/2003WO2003090759A1 Difructose anhydride-containing composition and use thereof
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090745A1 Fxr agonists for hepatoprotection and treatment of cholestasis
11/06/2003WO2003090743A1 Prevention and treatment of functional somatic disorders, including stress-related disorders
11/06/2003WO2003090742A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan
11/06/2003WO2003090740A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
11/06/2003WO2003090735A1 Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient
11/06/2003WO2003090731A1 Use of gabab receptor positive modulators in gastro-instestinal disorders
11/06/2003WO2003090704A1 Foods having effect of eliminating bad breath
11/06/2003WO2003090703A1 Oral care products containing ovomucin
11/06/2003WO2003090672A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
11/06/2003WO2003090662A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003076458A3 Selective dipeptide inhibitors of kallikrein
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003072711A3 Method of using modified oligonucleotides for hepatic delivery
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003055880A3 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003030613A3 Methods of treating liver fibrosis and hepatitis c virus infection
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003026589A3 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
11/06/2003WO2003018049A3 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003013428A3 Nutritional supplements and methods of using same
11/06/2003WO2003009855A3 Organo-phosphorous compounds for activating gamma/delta t cells
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002069993A8 Pharmaceutical composition made of cannabis extracts
11/06/2003WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
11/06/2003WO2002060900A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002058792A8 Rehydration composition
11/06/2003WO2002044210A3 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
11/06/2003WO2002034204A3 Calcilytic compounds
11/06/2003WO2002030408A3 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002018369A8 Peptidomimetic protease inhibitors
11/06/2003WO2002002096A8 Oral compositions comprising host-response modulating agent
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208082 Nitrogen compounds such as 4,5-diisopropyl-1-methyl-2-styryl -1H-imidazole, used as glutamate receptor antagonists, for prophylaxis of psychological disorders, as anxiolytic agents and analgesics
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207925 Methods of treatment with selective EP4 receptor agonists
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207900 2-substituted amino-bicyclic pyridine and pyrimidine compounds; for treatment of inflammation, inflammatory bowel disease, Alzheimer's disease, Crohn's disease, multiple sclerosis and asthma
11/06/2003US20030207898 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207875 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
11/06/2003US20030207874 Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207861 Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207807 A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and a protein
11/06/2003US20030207794 Compounds which are alpha -halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable
11/06/2003US20030207772 Warming and nonirritating lubricant compositions and method of comparing irritation
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030206963 Bone resorption suppressing agent
11/06/2003US20030206941 Fast dissolving orally consumable films
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003CA2711709A1 Oral care compositions containing ovomucin
11/06/2003CA2484090A1 Nitrosated imidazopyridines
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483515A1 Novel thiol derivative, method for producing the same and use thereof
1 ... 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 ... 1258